DOCUMENT NUMBER: SBMC-PPP-0637			
DOCUMENT TITLE: Nonrecollectable Specimens			
DOCUMENT NOTES:			
LOCATION: SBMC-rel	VERSION: <sub>02</sub>		
DOC TYPE: SBMC PPP	STATUS: Release		
EFFECTIVE DATE: 06 Jun 2025	NEXT REVIEW DATE: 06 Jun 2027		
RELEASE DATE: 06 Jun 2025	EXPIRATION DATE:		
AUTHOR:	PREVIOUS NUMBER:		
OWNER:	CHANGE NUMBER: SBMC-CR-0681		

## **Nonrecollectable Specimens**

#### **Purpose**

This document defines the process to manage nonrecollectable specimens in the SCPMG Laboratory Care Delivery System when specimens are not acceptable at time of receipt.

#### Scope

This policy is intended for laboratory personnel in the clinical laboratory who evaluate specimens submitted for acceptability.

#### **Definitions**

### Nonrecollectable Specimen (also known as Irreplaceable)

Specimens that cannot be recollected or when recollecting or reobtaining them would place the patient at significant risk. Examples are:

- Anatomic pathology and surgical specimens
- Specimens other than blood collected through invasive procedures such as:
  - Cerebrospinal aspiration
  - Fine-needle aspiration
  - Arthrocentesis
  - Bronchoscopy
  - Bone marrow aspiration
  - -Biopsy
  - Specimens collected during autopsy or by medical examiner
  - Suprapubic urine aspiration
- Specimens changed by intercurrent therapy, for which time or treatment affects results
  - Culture (including blood culture) when an antibiotic has subsequently been administered after specimen collection
  - Drug level when the drug has subsequently been administered after specimen collection
  - Drug level where drug has been administered prior to specimen collection for which a timed result is necessary
  - Specimens to monitor anticoagulant therapy
- Tests from newborns with limited blood volumes that preclude recollection

### **Policy**

- The laboratory must ensure specimens submitted are acceptable for testing.
- The laboratory must document when specimens are not acceptable for testing and subsequently accepted for testing.
  - Any exceptions are to be documented on the Specimen Labeling/Re-Labeling Waiver form or the Specimen Label Correction Log depending on local protocol. Use of both forms is not recommended.
  - All waivers completed or specimens logged will have an Unusual Occurrence Report (UOR) submitted to assist with investigation and development of corrective action as appropriate.
- The CLIA Director will make the final determination for cases in which nonrecollectability is in question or for exceptions to allow unacceptable recollectable specimens.
- The test result (report) must indicate information regarding the mislabeled specimen and the ordering provider or designee who completed the waiver/log.

#### **Process**

The following process is defined for handling unacceptable nonrecollectable specimens.

Step	Action				
1					
	If sample accessioning and	Then			
	testing occurs				
	Only in Clinical Laboratory	Notify appropriate Manager or			
	(includes testing performed at	designee (Go to step 2)			
	RRL or outside laboratories)				
	Only Cytology	Notify appropriate Manager or			
		designee (Go to step 2)			
	Only Anatomical Pathology (AP)	Follow normal process to forward			
		sample to AP laboratory for			
		accessioning/testing			
	Shared across clinical laboratory,	Notify managers/designees for			
	anatomical pathology, and/or	respective areas			
	cytology laboratories				

## Process, Continued

Step	Action		
2	For specimens received in the clinical laboratory the manager or designee will confirm specimen is nonrecollectable.  • If specimen is determined NOT to be nonrecollectable, or the provider/designee declines to complete the waiver or complete the log, then the manager/designee will direct laboratory staff to follow current process for cancellation and notification.  • Refer to step 12 for details.  • The manager or designee may consult with the CLIA Director or designee to determine if the specimen submitted qualifies as a Non recollectable Specimen		
	If medical center uses	Then	
	Specimen Labeling/Re-Labeling Waiver form	Go to Steps 3 and 4	
	Specimen Label Correction Log (local or regional version)	Go to Step 5	
3	The laboratory manager or designee will complete the following items on the <i>Specimen Labeling/Re-Labeling Waiver</i> form.  • Patient identifiers (top of form)  • Specimen source, test(s) ordered, accession number, collection date/time and error description (In the "To be completed by Laboratory Staff" section)  The form is then submitted/presented to the provider/designee.		
4	The provider or designee will complete the following items on the form in the "To be completed by Provider/Designee" section.  • The provider/designee name (printed) and signature fields.  • Check a reason that specimen cannot be replaced/recollected.  – For the reason of "Other" a reason can be completed  The form and corrected specimen are then resubmitted to the laboratory.  Go to Step 6		
5	Alternatively, the use of the <i>Specimen Label Correction Log</i> can be used  • Ensure the Date, Time, MRN, Patient Name, Reason for Label Correction, and Correction Made by columns are correctly completed prior to proceeding to next step.		

## Process, Continued

Step	Action			
6	The corrected specimen will be electronically documented in the appropriate laboratory information system(s)			
	If Then			
	Cerner: Accessioned by MC/MOB staff	The laboratory manager or designee will add the following <b>Order Comment</b> to Cerner: "Unlabeled/mislabeled specimen submitted, corrected by after submission to		
	Co-Path: The laboratory manager or designee will add a accessioned by MC/MOB staff The specimen will be transported to Cytology			
		using current processes.		
	Co-Path: NOT accessioned by MC/MOB staff	The specimen will be transported to Cytology using current processes. with a copy of the completed form/log		
7	The laboratory manager or designee will sign, date/time the waiver form or log.  This signature signifies that the waiver form/log has been reviewed:  • For completeness  • That applicable order comment/deficiency has been placed in Cerner/Co-Path  — If unable to enter deficiency comment into Co-Path a copy of the completed waiver form/log is forwarded with the specimen.			
8	The laboratory manager or designee will release the specimen.			
9	The laboratory Quality Manager/Designee will review the waiver form and sign, date/time.  • This signature signifies that the waiver form has been reviewed for			
	completeness, the c Cerner/CoPath, and	order comment/deficiency entry has been placed in dan UOR was submitted.		
10	The laboratory CLIA Director/Designee will review the waiver form and sign, date/time the waiver form.			
11	-	ogs will be retained per current records retention		

### Process, Continued

Step	Action		
12	If the specimen is determined <b>NOT to be nonrecollectable</b> OR If the ordering provider or designee <b>declines</b> the option to correct the error and sign the waiver/form, the test will be cancelled in the applicable systems (Cerner or CoPath).		
	IF	AND	THEN
	Sample is accessioned in Cerner	Not a GYN sample	Cancel order and Add <b>Order Comment</b> to Cerner:  "Provider xxx notified @ date/time"
	Sample is accessioned in Cerner	Is a GYN sample	Cancel order and Add <b>Order</b> Comment to Cerner: "Provider xxx notified @ date/time" AND Forward sample to Cytology to cancel Pap test in CoPath
	Sample is accessioned in Co- Path only (GYN Sample for Pap)	Co-Path accessioning is <b>not</b> performed by MC/MOB	Forward specimen to Cytology to accession/cancel Pap test in CoPath
	Sample is accessioned in Co-Path only  Submit an UOR for mi	Co-Path accessioning is performed by MC/MOB	Follow current process for order management.

Non- Controlled Documents	The following non-controlled document supports this policy.  • CAP Laboratory General Checklist, All Common
Controlled Documents	The following controlled documents support this policy.  • Specimen Acceptance and Rejection  • Specimen Labeling/Re-Labeling Waiver form  • Specimen Label Correction Log
Authors	PreAnalytic Processing Working Group

Regional Parent Document Reference Number: SCPMG-PPP-0404 Rev: 02

## **Signature Manifest**

**Document Number:** SBMC-PPP-0637 **Revision:** 02

**Title:** Nonrecollectable Specimens **Effective Date:** 06 Jun 2025

All dates and times are in Pacific Standard Time.

## Nonrecollectable Specimens

## **Operations Director Approval**

Name/Signature	Title	Date	Meaning/Reason
Carlo Punu (F316195)	DIR OPER AREA LAB	14 Apr 2025, 01:05:02 PM	Approved

## **Medical Director Approval**

Name/Signature	Title	Date	Meaning/Reason
Christopher Hale (K706810)	CLIA Director	14 Apr 2025, 01:29:05 PM	Approved